Silo Pharma Selects Veloxity Labs for Bioanalytical IND-Enabling Study for our Novel Intranasal PTSD Therapy, SPC-15

Core Insights - Silo Pharma, Inc. has engaged Veloxity Labs for bioanalysis to support the ongoing GLP-compliant toxicology study of its lead asset, SPC-15, which is an intranasal treatment for PTSD [1][2] - The company anticipates starting the FDA IND process for SPC-15 in 2025, with plans to proceed to a Phase 1 clinical trial upon IND approval [2] Company Overview - Silo Pharma is a developmental stage biopharmaceutical company focused on addressing underserved conditions such as stress-induced psychiatric disorders, chronic pain, and CNS diseases [3] - The company's portfolio includes innovative programs like SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer's disease and multiple sclerosis [3] - Research is conducted in collaboration with leading universities and laboratories [3]